Theravance Biopharma(TBPH) - 2024 Q3 - Quarterly Results

Exhibit 99.1 Theravance Biopharma, Inc. Reports Third Quarter 2024 Financial Results and Announces Initiatives to Unlock Shareholder Value · Third quarter results highlight strong operational performance across key value drivers: o YUPELRI (revefenacin) net sales of $62.2 million, recognized by Viatris, an all-time high, increased 7% versus Q3 2023 and 14% versus Q2 2024 o CYPRESS enrollment in-line with expectations, with timelines on track o TRELEGY net sales increased 17%, to $789 million, as reported by ...